Spots Global Cancer Trial Database for eribulin
Every month we try and update this database with for eribulin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer | NCT05402722 | TNBC - Triple-N... | Eribulin anti-PD-1 antib... | 18 Years - 75 Years | Beijing 302 Hospital | |
| Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer | NCT02863146 | Breast Cancer Metastatic Brea... | 18 Years - | Centre Oscar Lambret | ||
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | NCT02616848 | Triple Negative... | Everolimus Eribulin | 18 Years - | Istituti Ospitalieri di Cremona | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| First Line Metastatic Breast Cancer Treatment (ESMERALDA) | NCT01941407 | Metastatic Brea... | Eribulin | 18 Years - | ARCAGY/ GINECO GROUP | |
| Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | NCT03795012 | Breast Cancer | Eribulin | 18 Years - | MedSIR | |
| A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | NCT06279364 | Triple Negative... | SKB264 Paclitaxel Nab-paclitaxel Capecitabine Eribulin Carboplatin | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | NCT06263231 | Sarcoma,Soft Ti... | INT230-6 Eribulin Trabectedin Pazopanib | 18 Years - | Intensity Therapeutics, Inc. | |
| Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | NCT02404506 | Breast Cancer Adenocarcinoma | Eribulin mesila... | 70 Years - | Swiss Group for Clinical Cancer Research | |
| PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin | NCT05810870 | Breast Cancer Advanced Breast... Metastatic Brea... | MEN1611 Eribulin | 18 Years - | MedSIR | |
| Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study | NCT04913571 | Triple Negative... | Eribulin Tislelizumab | 18 Years - 70 Years | Fudan University | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | NCT01554371 | Malignant Solid... Breast Cancer N... Neuropathy | Eribulin Cyclophosphamid... | 18 Years - 80 Years | University of California, San Francisco | |
| Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment | NCT02061085 | Breast Neoplasm Metastasis | Eribulina | 18 Years - | MedSIR | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | NCT06387628 | TNBC - Triple-N... | LM-108 Toripalimab Eribulin Nab paclitaxel | 18 Years - 75 Years | Fudan University | |
| A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | NCT06435429 | Metastatic HER2... | Zanidatamab Trastuzumab Eribulin Vinorelbine Gemcitabine Capecitabine | 18 Years - | Jazz Pharmaceuticals | |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | NCT03901339 | Metastatic Brea... | Sacituzumab Gov... Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - | Gilead Sciences | |
| Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) | NCT04517292 | Breast Cancer | Eribulin,cispla... Gemcitabine,cis... | 18 Years - 70 Years | Fudan University | |
| A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | NCT03264547 | Breast Cancer | Pertuzumab Trastuzumab Docetaxel Paclitaxel Eribulin | 20 Years - 70 Years | Japan Breast Cancer Research Group | |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | NCT03901339 | Metastatic Brea... | Sacituzumab Gov... Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - | Gilead Sciences | |
| Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer | NCT02551263 | Breast Cancer | Eribulin | 20 Years - 75 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Extended Treatment in Metastatic Breast Cancer With Eribulin | NCT02769364 | Breast Cancer | 18 Years - | Eisai Inc. | ||
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | NCT03430518 | HER2-Negative M... Recurrent Ovari... | Durvalumab Eribulin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | NCT06081959 | Metastatic Brea... | SKB264 Eribulin Capecitabine Gemcitabine Vinorelbine | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | NCT06202313 | Triple Negative... | Cadonilimab Eribulin | 18 Years - 75 Years | Shengjing Hospital | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | NCT04681911 | Breast Cancer | Inetetamab Pyrotinib Capecitabine Gemcitabine Vinorelbine Carboplatin Albumin paclita... Eribulin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy | NCT03027245 | Locally Advance... | Eribulin | 18 Years - | Eisai Inc. | |
| Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue | NCT02645175 | Metastatic Brea... Fatigue | TW1025 Placebo | 18 Years - 80 Years | Meriyana Bio Inc. | |
| A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors | NCT00908908 | Advanced Solid ... | eribulin | 18 Years - | Eisai Inc. | |
| Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | NCT03786094 | Metastatic Brea... Locally Recurre... | Eribulin Balixafortide | 18 Years - | Spexis AG | |
| Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | NCT01705691 | Breast Cancer HER2-negative B... | Paclitaxel Eribulin Doxorubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | NCT01498588 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of the B... Neoplasms, Brea... Tumors, Breast | Eribulin Doxorubicin Cyclophosphamid... Pegfilgrastim | 18 Years - | Emory University | |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | NCT02915744 | Metastasis Breast Cancer | NKTR-102 Eribulin Ixabepilone Vinorelbine Gemcitabine Paclitaxel Docetaxel Nab-paclitaxel | 18 Years - | Nektar Therapeutics | |
| Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer | NCT02863146 | Breast Cancer Metastatic Brea... | 18 Years - | Centre Oscar Lambret | ||
| Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | NCT03786094 | Metastatic Brea... Locally Recurre... | Eribulin Balixafortide | 18 Years - | Spexis AG | |
| Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer | NCT02551263 | Breast Cancer | Eribulin | 20 Years - 75 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer | NCT05402722 | TNBC - Triple-N... | Eribulin anti-PD-1 antib... | 18 Years - 75 Years | Beijing 302 Hospital | |
| Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer | NCT02263495 | Metastatic Brea... | Paclitaxel Eribulin Gemcitabine | 19 Years - | Asan Medical Center | |
| Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | NCT06202313 | Triple Negative... | Cadonilimab Eribulin | 18 Years - 75 Years | Shengjing Hospital | |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | NCT03899805 | Sarcoma Liposarcoma Leiomyosarcoma Undifferentiate... | Eribulin Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients | NCT01795586 | Breast Cancer | Eribulin Carboplatin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination | NCT01585870 | Neoplasms | Sorafenib (Nexa... Eribulin | 18 Years - | Bayer | |
| Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination | NCT01585870 | Neoplasms | Sorafenib (Nexa... Eribulin | 18 Years - | Bayer | |
| Study of Eribulin in Children With Cancer to Determine Safety | NCT02082626 | Pediatric Cance... Solid Tumors Lymphoma | Eribulin mesyla... | - 20 Years | University of Oklahoma | |
| Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer | NCT05302778 | Breast Cancer Metastatic Brea... Triple Negative... | 18 Years - | University of Milano Bicocca | ||
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | NCT02623972 | Inflammatory Br... Human Epidermal... | Eribulin Adriamycin Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Eribulin and Lenvatinib in Advanced Solid Tumors | NCT02640508 | Cancer Solid Tumor | Eribulin Lenvatinib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | NCT03734029 | Breast Cancer | Trastuzumab der... Capecitabine Eribulin Gemcitabine Paclitaxel Nab-paclitaxel | 18 Years - | Daiichi Sankyo | |
| A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | NCT06435429 | Metastatic HER2... | Zanidatamab Trastuzumab Eribulin Vinorelbine Gemcitabine Capecitabine | 18 Years - | Jazz Pharmaceuticals | |
| Eribulin in mTNBC Patients | NCT04541420 | Breast Cancer | - | Fudan University | ||
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients | NCT02175446 | Metastatic Brea... Human Epidermal... | Bevacizumab and... | 18 Years - | Consorzio Oncotech | |
| Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate | NCT02581839 | Metastatic Brea... Brain Metastase... | Eribulin Mesyla... MRI Pre-Medication:... Pre-Medication:... | 18 Years - | Case Comprehensive Cancer Center | |
| Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | NCT01401959 | Metastatic Brea... | Eribulin Trastuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | NCT01596751 | Metastatic Brea... | PLX3397 Eribulin | 18 Years - | University of California, San Francisco | |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | NCT02915744 | Metastasis Breast Cancer | NKTR-102 Eribulin Ixabepilone Vinorelbine Gemcitabine Paclitaxel Docetaxel Nab-paclitaxel | 18 Years - | Nektar Therapeutics | |
| Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | NCT03734029 | Breast Cancer | Trastuzumab der... Capecitabine Eribulin Gemcitabine Paclitaxel Nab-paclitaxel | 18 Years - | Daiichi Sankyo | |
| Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment | NCT02061085 | Breast Neoplasm Metastasis | Eribulina | 18 Years - | MedSIR | |
| A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | NCT06006273 | Refractory Soli... | Eribulin Irinotecan Temozolomide | 1 Year - 25 Years | M.D. Anderson Cancer Center | |
| PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) | NCT02723877 | Metastatic Brea... | PQR309 Eribulin | 18 Years - | PIQUR Therapeutics AG | |
| Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate | NCT02581839 | Metastatic Brea... Brain Metastase... | Eribulin Mesyla... MRI Pre-Medication:... Pre-Medication:... | 18 Years - | Case Comprehensive Cancer Center | |
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | NCT03430518 | HER2-Negative M... Recurrent Ovari... | Durvalumab Eribulin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients | NCT01802970 | Metastatic Brea... | Anakinra plus S... | 18 Years - 80 Years | Baylor Research Institute | |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | NCT03331250 | Angiosarcoma Epithelioid Hem... | Eribulin | 18 Years - | Massachusetts General Hospital | |
| Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer | NCT01388647 | HER-2 Positive ... | eribulin carboplatin trastuzumab | 18 Years - | Vector Oncology | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | NCT05063786 | Advanced Breast... | Trastuzumab Alpelisib Fulvestrant Vinorelbine Capecitabine Eribulin | 18 Years - | Spanish Breast Cancer Research Group | |
| Extended Treatment in Metastatic Breast Cancer With Eribulin | NCT02769364 | Breast Cancer | 18 Years - | Eisai Inc. | ||
| Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | NCT06268652 | Breast Cancer Refractory Brea... | Organoid-guided... Gemcitabine Capecitabine Vinorelbine Eribulin | 18 Years - | Sun Yat-sen University | |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | NCT06099769 | Metastatic Brea... | Enzalutamide Mifepristone TPC | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | NCT03331250 | Angiosarcoma Epithelioid Hem... | Eribulin | 18 Years - | Massachusetts General Hospital | |
| Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | NCT04745975 | Triple Negative... | Personalized tr... Nab paclitaxel Eribulin Vinorelbine Gemcitabine Capecitabine | 18 Years - 70 Years | Fudan University | |
| A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | NCT04303741 | Breast Cancer | Camrelizumab Apatinib Eribulin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | NCT05063786 | Advanced Breast... | Trastuzumab Alpelisib Fulvestrant Vinorelbine Capecitabine Eribulin | 18 Years - | Spanish Breast Cancer Research Group | |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | NCT06387628 | TNBC - Triple-N... | LM-108 Toripalimab Eribulin Nab paclitaxel | 18 Years - 75 Years | Fudan University | |
| Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | NCT02555657 | Metastatic Trip... | pembrolizumab capecitabine eribulin gemcitabine vinorelbine | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
